BTG Establishes Collaboration Agreement With Collegium Pharmaceutical Inc. To Develop Innovative Therapy For Sleep Apnea 
10/19/2005 5:09:18 PM

BTG (LSE: BGC), the intellectual property and technology commercialization company, announced today that it has entered into a Collaboration Agreement with Collegium Pharmaceutical, Inc., to develop novel formulations of its combination drug therapy currently being developed for the treatment of sleep apnea. Collegium will employ its expertise in product development, including its suite of proprietary formulation technologies, with the goal of establishing a broadly patented single product with optimal properties for the treatment of this sleep-related breathing disorder. The Collaboration Agreement provides for a development program that will be funded by BTG, as well as a revenue sharing arrangement between the parties. The intent of this Collaboration Agreement is for the sleep apnea project to be the first of additional co-development programs between the companies.